Aptose Biosciences is a clinical-stage biotechnology company developing differentiated therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research. The company's pipeline includes small molecules designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
2020 AACR Presentation - Early clinical findings from a Phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with R/R CLL/SLL or NHLView This Presentation
Pharmaceutical Preparation Manufacturing (325412)
Pharmaceutical and Medicine Industry (3741)
Aptose Biosciences Inc.
12770 High Bluff Drive
San Diego, CA 92130